V25: PROCESS DEVELOPMENT FOR VACCINE CANDIDATES INCLUDING SARS-COV-2

V25：包括 SARS-COV-2 在内的候选疫苗的工艺开发

• 批准号: 10168830
• 负责人: THOMAS HASSEL
• 金额: $ 2.03万
• 依托单位: INTERNATIONAL AIDS VACCINE INITIATIVE
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-05-15 至 2028-05-14
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10168830
• 关键词: 2019-nCoV; Adjuvant; Biological; Bioterrorism; COVID-19; Clinical Research; Communicable Diseases; Contracts; Cyclic GMP; Development; Development Plans; Emerging Communicable Diseases; Phase; Process; Services; System; United States Food and Drug Administration; Vaccines; novel coronavirus; novel vaccines; product development; vaccine candidate; vaccine delivery; vaccine development

The Manufacture and Characterization Services (MCS) for Vaccines and Other Biologics for Infectious Diseases contract provides a variety of services spanning product development planning and feasibility assessments; product optimization; product development and cGMP compliant manufacture for Phase I/II clinical studies; technical and facility audits; and regulatory support appropriate for submission to the U.S. Food and Drug Administration (FDA). These services will facilitate the development and introduction of new vaccines and biologics against potential agents of bioterrorism and emerging and re-emerging infectious diseases. This contract also provides for manufacture of vaccines, vaccine components including adjuvants, vaccine delivery systems, other biologics, and challenge material.

传染病合同的疫苗和其他生物制剂的制造和表征服务（MCS）提供了各种服务跨越产品开发计划和可行性评估的服务；产品优化； I/II期临床研究的产品开发和CGMP符合CGMP的制造；技术和设施审核；以及适合向美国食品药品监督管理局（FDA）提交的监管支持。 这些服务将有助于开发和引入新的疫苗和生物制剂，以针对生物恐怖主义的潜在药物以及新兴和重新出现的传染病。 该合同还提供了疫苗，包括佐剂，疫苗输送系统，其他生物制剂和挑战材料在内的疫苗成分的生产。